Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

FHS
June 12, 2024
10:52 am

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

Biotech Showcase™ marking 17 years of innovation and opportunity – Biotech Investments

EQS-News: EBD Group / Key word(s): Conference Biotech Showcase™ marking 17 years of innovation and opportunity 27.11.2024 / 11:34 CET/CEST The issuer is solely responsible

November 28, 2024

FDA approves innovative T cell immunotherapy for rare soft-tissue cancer

LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a rare cancer that arises in the body’s soft tissues, extending

August 2, 2024

Rigid rules at methadone clinics are jeopardizing patients’ path to recovery from opioid addiction

You’re reading Part 2 of The War on Recovery, a yearlong investigation into how the U.S. denies lifesaving medications to people with opioid addiction. Read

March 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.